EUSA Erwinaze approval shows major pharma how to win in orphan markets, says CEO
This article was originally published in Scrip
In what the company is calling a transformative event, EUSA Pharma, a specialty pharmaceutical company focused on oncology, announced that the US FDA has approved its orphan drug Erwinaze (asparaginase Erwinia chrysanthemi) for the treatment of acute lymphoblastic leukaemia in patients with hypersensitivity to E. coli-derived asparaginase.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.